anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We recently derived a novel TMS target for anxiety via lesion and brain stimulation mapping methods. We prospectively tested this target in a sample of participants with major depressive disorder (MDD) with comorbid anxiety symptoms and found that it was more effective for anxiety (median change 60.0% vs 39.8%, p=0.01) than the conventional TMS target for MDD with comorbid anxiety. While these results are promising, it remains unclear how our target works for anxiety-related disorders as opposed to MDD comorbid anxiety symptoms. Furthermore, we used conventional 10 Hz TMS, but accelerated intermittent theta burst stimulation (aiTBS) has now been shown to improve outcomes and is now an FDA approved treatment protocol. Finally, we tested the translational hypothesis that stimulating different circuits can modify different behaviors; clinical efficacy was a secondary outcome.

This double-blinded, randomized, sham-controlled aiTBS trial will test the efficacy of our novel anxiety target. 80 participants with anxiety-related disorders (i.e., panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder) will receive 50 active or sham TMS treatments over 5 days. Changes in anxiety symptoms/processes will be assessed via validated measures (primary outcome measure: Beck Anxiety Inventory) during treatment and follow-up visits up to one-year post-treatment. Participants randomized to sham who do not respond will be offered an open-label crossover extension.
NEW MATERIAL:A compound shown by the formula. USE:A drug and an agricultural chemical. A lipid compound of spermidine bonded to a fatty acid by amide bond in a cell of bacterium. PREPARATION:A bacterium belonging to the genus Acetobacter or Gluconobacter is cultured in a medium at pH <=5 and a culture mixture is extracted with an organic solvent such as methanol. Then the extract is purified by column chromatography to give a compound shown by formula. The fatty acid having amide bond is obtained by hydrolyzing a compound shown by the formula with hydrochloric acid and subjecting to gas chromatography or the fatty acid having ester bond is obtained by decomposing the compound shown by the formula with a weak alkali, converting to a methyl ester derivative and subjecting to gas chromatography.
The invention discloses an ezetimibe eutectic crystal and a preparation method thereof, and particularly relates to an ezetimibe drug-nicotinamide eutectic crystal and a preparation method thereof, belonging to the technical field of drug eutectic crystals. Ezetimibe is used as the drug active component (API), and nicotinamide is used as a eutectic crystal precursor (CCF) to form the ezetimibe-nicotinamide eutectic crystal. The preparation method adopts a solid milling process and comprises the following steps: proportionally adding the ezetimibe and nicotinamide in a ball mill, adding a trace amount of alcohol solvent, and milling. After the ezetimibe-nicotinamide eutectic crystal is subjected to structural characterization through P-XRD, DSC (differential scanning calorimetry), IR and SEM, the eutectic melting point is 106-110 DEG C, and no melting point peaks of API and CCF exist in the eutectic DSC spectrogram. The solubility and dissolution of the ezetimibe eutectic crystal are obviously improved. The method only needs a small amount of solvent, generates fewer byproducts, is simple to operate, can be easily applied in industrial pharmacy, and conforms to the requirements for environmental protection.
The invention belongs to the field of high polymer materials, and discloses a composite fiber containing aggregation-induced luminescent molecules, a preparation method thereof and an application thereof. The preparation method of the composite fiber comprises the steps of adding aggregation-induced luminescent molecules into a high polymer material solution or a solution of a high polymer material and a carrier, uniformly mixing the solution, and preparing the composite fiber through the electrostatic spinning process. The composite fiber containing aggregation-induced luminescent molecules has multiple types of AIE, and is strong in fluorescence intensity. Therefore, the composite fiber can meet the requirements of different fluorescent staining operations. The preparation method provided by the invention is simple, high in production efficiency, and good in repeatability. The composite fiber containing aggregation-induced luminescent molecules can be applied in the fields of cell positioning and imaging, fiber microstructure observation, fiber drug loading and the like.
BACKGROUND: Several studies pointed out the importance of genetic risk factors such as parental consanguinity (PC) and familial multiple sclerosis (FMS) in the risk of MS. This study aimed to investigate the PC and FMS among people with MS (pwMS) in Isfahan, Iran.
METHODS: This case-control study was conducted on pwMS from the MS clinic of Kashani Hospital, Isfahan, Iran, in October 2023. A group of healthy controls (HC) were also recruited. Data on demographic and clinical characteristics and history of PC and FMS were collected from participants. The relationships between PC, FMS, and developing MS were assessed using multinomial logistic regression analysis. The odds ratio (OR) with a 95% confidence interval (CI) was computed.
RESULTS: A total number of 4264 pwMS and 400 HCs were included. The prevalence of PC and FMS among pwMS were 29.3% and 24%, respectively. Multinomial logistic regression adjusted for age and sex indicated that the odds of developing MS were significantly associated with a history of PC (OR = 3.03, 95% CI 2.23 to 4.13, p < 0.001) and FMS (OR = 5.42, 95% CI 3.51 to 8.38, p < 0.001).
CONCLUSION: PC and FMS can increase the risk of developing MS. They should be considered along with other risk factors for developing MS. A comprehensive conclusion requires further research.
Potential subjects will be interviewed over the phone and, if appropriate, will be scheduled for a screening session. Participants who meet study criteria will participate in two study sessions separated by at least two weeks. The sessions will be identical except on one day they will receive guanfacine and on the other, they will receive a placebo.

This study was initially completed in 2014. Upon analysis of the collected data, it was decided to add additional subjects and gather additional data to verify results seen in the collected data. The study was reopened and new data was added beginning in September 2016. Information about the study beginning in 2016 is available in a separate record.
Provided are a method of preparing an antibody with a regulated, sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content, a method of preparing a high-quality population of antibodies by regulating the sugar content of the antibody to a desired content, and a population of antibodies prepared by the method. Further, provided is a method of regulating the antibody sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content. Furthermore, provided is a medium composition, for regulating the antibody sugar chain content, the medium composition including glycerol as an additive for regulating the antibody sugar chain content. The preparation method of antibodies according to the present invention may be used to prepare a desired high-quality population of antibodies by regulating the sugar chain content of the antibody. Further, in terms of the development of biosimilars, the method of the present, invention may be used to regulate the sugar chain, content of antibodies, thereby preparing antibodies having high equivalence to a control drug. Since the sugar chain content may be regulated by a medium composition, the regulation method is easy and efficient in terms of time and cost, and therefore, widely applied to the fields of antibody preparation.
Nosocomial infections threaten patient safety, and were widely reported during the COVID-19 pandemic. Effective hospital infection control requires a detailed understanding of the role of different transmission pathways, yet these are poorly quantified. Using patient and staff data from a large UK hospital, we demonstrate a method to infer unobserved epidemiological event times efficiently and disentangle the infectious pressure dynamics by ward. A stochastic individual-level, continuous-time state-transition model was constructed to model transmission of SARS-CoV-2, incorporating a dynamic staff-patient contact network as time-varying parameters. A Metropolis-Hastings Markov chain Monte Carlo (MCMC) algorithm was used to estimate transmission rate parameters associated with each possible source of infection, and the unobserved infection and recovery times. We found that the total infectious pressure exerted on an individual in a ward varied over time, as did the primary source of transmission. There was marked heterogeneity between wards; each ward experienced unique infectious pressure over time. Hospital infection control should consider the role of between-ward movement of staff as a key infectious source of nosocomial infection for SARS-CoV-2. With further development, this method could be implemented routinely for real-time monitoring of nosocomial transmission and to evaluate interventions.
PURPOSE:To obtain a low-cost bathing agent safe to the human body and having a warm bathing effect, a cosmetic effect and a medicinal effect in combination. CONSTITUTION:This bathing agent is a component itself selected from the components mentioned below or contains it; (1) A ground powder of rice or germinated rice. (2) An extract of rice or germinated rice. (3) A material obtained by allowing a decomposing enzyme or a malt to act on a mixture of rice or germinated rice and water. (4) A material obtained by extracting rice or germinated rice before, during or after allowing a decomposing enzyme or a malt to act thereon. (5) A material obtained by subjecting alcohol or an organic acid fermertation to the extract of rice or germinated rice or to the product by allowing a decomposing enzyme or a malt to act thereon.
Hepatocellular carcinoma (HCC) or primary liver cancer is the third leading cause of cancer death worldwide. It accounts for 90% of all liver cancers. More than 80% of patients present with advanced or unresectable disease.

For patients with vascular invasion and/or metastases, the only approved therapy that offers a survival advantage is Sorafenib (Nexavar®). While palliative systemic chemotherapy other than Sorafenib is sometimes offered for HCC, there is no evidence that any chemotherapy has any meaningful therapeutic benefit, especially in overall survival. Subjects in the current study will either have completed at least 90 days of sorafenib treatment or are not able to receive sorafenib due to intolerability or unable to afford. Subjects will continue sorafenib as tolerated while receiving experimental therapy. The experimental dosing schedule has four segments: (1) priming, which consists of intradermal AlloStim alone; (2) vaccination, which consists of intradermal dosing of AlloStim+CRCL; (3) activation, which consists of an intravenous infusion of AlloStim; and (4) booster, which consists of monthly intradermal injections of CRCL alone
However, Acute mesenteric ischemia represents a major diagnostic challenge because of its varied presentations and multiple causes . Patients usually present with non-specific abdominal symptoms and laboratory findings, which leads to delayed diagnoses . Therefore, diagnostic imaging has emerged as one of the most crucial components in the diagnostic work-up of suspected

Recent technical advances have made computed tomography angiography the modality of choice in the setting of suspected Acute mesenteric ischemia.computed tomography angiography is a rapid and non-invasive diagnostic tool for assessing intestinal vasculature and bowel . computed tomography angiography allows early diagnosis and differentiation between occlusive and non-occlusive causes, which is important to direct therapeutic approach . Overall, combining vascular and bowel assessment results in a high diagnostic accuracy . A recent meta-analysis showed a sensitivity of 93% and a specificity of 96% . However, this meta analysis also showed that the prevalence of confirmed .Acute mesenteric ischemia is less than 25% among the patients referred to computed tomography angiograph in the setting of suspected Acute mesenteric ischemia .Knowledge of the prevalence and the demographic distribution of alternative diagnoses in the remaining three-fourths of patients without Acute mesenteric ischemia is important for appropriate patient care. computed tomography angiograph is considered to allow for a variety of acute alternative diagnoses, ensuring timely triage of these patients.
The present invention provides compositions for altering a B cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the V H  or V L  region of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding V H  and/or V L  regions and the genes encoding immunoglobulin constant regions are isolated and inserted in an expression vector. The chimeric proteins may be produced by introducing the expression vectors into insect cell lines. Proteins may be further purified and conjugated to a compound such as an immunogenic carrier.
1278040 Analgesic compositions ELI LILLY & CO 1 June 1970 [3 June 1969] 26353/70 Heading A5B Compositions having enhanced analgesic activity comprise one part by weight of a compound of the formula:  wherein R 1  is methyl or ethyl and R 2  is dimethylamino or pyrrolidino or a pharmaceutically acceptable acid addition salt thereof (e.g. the hydrochloride, hydrobromide, sulphate, bisulphate, acetate, valerate, oleate, phenate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate or napsylate) and from 0.5 to 3 parts by weight of indomethacin or a pharmaceutically acceptable cationic salt thereof (e.g. alkali metal such as Na, K; alkaline earth metal such as Ba or Ca, or Al or Mg salts). α-d-propoxy phene is the preferred compound having the above formula. The compositions may be administered orally or rectally in the form of capsules, tablets, pills, powders, granules, emulsions, solutions, suspensions, syrups, elixirs or suppositories. The compositions may also contain at least one other therapeutic ingredient e.g. acetylsalicylic acid.
Prolonged ventilation is a complication of spontaneous supratentorial hemorrhage patients, but the predictive relationship with successful weaning in this patient cohort is not understood. Here, we evaluate the incidence and factors of ventilation weaning in case of spontaneous supratentorial hemorrhage. We retrospectively studied data from 166 patients in the same hospital from January 2015 to March 2021 and analyzed factors for ventilation weaning. The clinical data recorded included patient age, gender, timing of operation, initial Glasgow Coma Scale (GCS), Intracranial hemorrhage (ICH) score, alcohol drinking, cigarette smoking, medical comorbidity, and the blood data. Predictors of patient outcomes were determined by the Student t test, chi-square test, and logistic regression. We recruited and followed 166 patients who received operation for spontaneous supratentorial hemorrhage with cerebral herniation. The group of successful weaning had 84 patients and the group of weaning failed had 82 patients. The patient's age, type of operation, GCS on admission to the Intensive care unit (ICU), GCS at discharge from the ICU, medical comorbidity was significantly associated with successful weaning, according to Student t test and the chi-square test. According to our findings, patients with stereotaxic surgery, less history of cardiovascular or prior cerebral infarction, GCS >8 before admission to the hospital for craniotomy, and a blood albumin value >3.5 g/dL have a higher chance of being successfully weaned off the ventilator within 14 days.
In reconstructive surgery, complications post-fibula free flap (FFF) reconstruction, notably peri-implant hyperplasia, are significant yet understudied. This study analyzed peri-implant hyperplastic tissue surrounding FFF, alongside peri-implantitis and foreign body granulation (FBG) tissues from patients treated at the Department of Oral and Maxillofacial Surgery, Seoul National University Dental Hospital. Using light microscopy, pseudoepitheliomatous hyperplasia, anucleate and pyknotic prickle cells, and excessive collagen deposition were observed in FFF hyperplastic tissue. Ultrastructural analyses revealed abnormal structures, including hemidesmosome dilation, bacterial invasion, and endoplasmic reticulum (ER) swelling. In immunohistochemical analysis, unfolded protein-response markers ATF6, PERK, XBP1, inflammatory marker NFκB, necroptosis marker MLKL, apoptosis marker GADD153, autophagy marker LC3, epithelial-mesenchymal transition, and angiogenesis markers were expressed variably in hyperplastic tissue surrounding FFF implants, peri-implantitis, and FBG tissues. NFκB expression was higher in peri-implantitis and FBG tissues compared to hyperplastic tissue surrounding FFF implants. PERK expression exceeded XBP1 significantly in FFF hyperplastic tissue, while expression levels of PERK, XBP1, and ATF6 were not significantly different in peri-implantitis and FBG tissues. These findings provide valuable insights into the interconnected roles of ER stress, necroptosis, apoptosis, and angiogenesis in the pathogenesis of oral pathologies, offering a foundation for innovative strategies in dental implant rehabilitation management and prevention.
FIELD: biotechnology, biochemistry, enzymology. SUBSTANCE: cattle frozen organs were homogenized, and the protease basic inhibitor is extracted with an acid aqueous solution at pH = 1-3. The obtained extract is fractionated and concentrated by ultrafiltration at tangential flow on the hollow fibers (firstly at pore size is 15-50 kDa and then at 5 kDa). Final purification is carried out by cation-exchange chromatography. Yield and specific activity of the end product were increased by 8- and 10.8-fold, respectively. Invention can be used in medicine, cellular and molecular biology. EFFECT: increased yield and specific activity, simplified technology, decreased cost. 2 cl
This application discloses methods for prevention and treatment of cancers. Due to the larger size of human white blood cells compared to red blood cells, a decrease in the diameter of a part of a blood vessel can block the flow of white blood cells while allowing the flow of red blood cells. As a result, in tissues with such reduction in the diameter of blood vessels, there are areas where red blood cells are present, while there is a lack of white blood cells to fight the parasites and cancer cells. Therefore, cancer cells and other parasites can reside in such areas, replicate, and develop into diseases. 
     The disclosed methods provide for widening of the blood vessels in which a reduction in the diameter of a part of the vessel blocks the flow of white blood cells, while allowing the flow of red blood cells. As a result of this widening, white blood cells may pass through the vessel, reach to the parasites or cancer cells, and confront them. The disclosed methods include administration of vasodilators, blood fat-reducing drugs, anti-inflammatory agents, or blood clot-reducing medications. The claimed methods may be used in combination with other conventional methods for treating cancers.
Subjects will use the FlowSmart Infusion Set for a period of 9 to 11 days, then switch to their current infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period then - Subjects will use their current infusion set for a period of 9 to 11 days, then switch to the FlowSmart infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period.
BACKGROUND: We aimed to prospectively evaluate the association between a diabetes risk reduction diet (DRRD) score and the risk of liver cancer development and chronic liver disease-specific mortality.
METHODS: We included 98,786 postmenopausal women from the Women's Health Initiative-Observational Study and the usual diet arm of the Diet Modification trial. The DRRD score was derived from eight factors: high intakes of dietary fiber, coffee, nuts, polyunsaturated fatty acids, low intakes of red and processed meat, foods with high glycemic index, sugar-sweetened beverages (SSBs), and trans fat based on a validated Food-Frequency Questionnaire administered at baseline (1993-1998). Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for liver cancer incidence and chronic liver disease mortality were estimated using Cox proportional hazards regression models.
RESULTS AND CONCLUSION: After a median follow-up of 22.0 years, 216 incident liver cancer cases and 153 chronic liver disease deaths were confirmed. A higher DRRD score was significantly associated with a reduced risk of developing liver cancer (HRTertile 3 vs. Tertile 1 = 0.69; 95% CI: 0.49-0.97; Ptrend = 0.03) and chronic liver disease mortality (HRT3 vs. T1 = 0.54; 95% CI: 0.35-0.82; Ptrend = 0.003). We further found inverse associations with dietary fiber and coffee, and positive associations with dietary glycemic index, SSBs, and trans fat. A higher DRRD score was associated with reduced risk of developing liver cancer and chronic liver disease mortality among postmenopausal women.
BACKGROUND: Whether genetic susceptibility to cardiovascular diseases (CVDs) enhances the vulnerability to adverse cardiovascular outcomes by air pollution is unknown. We assessed the combined effect of air pollution and genetic predispositions on CVD risk.
METHODS AND RESULTS: From the UK Biobank cohort, we selected genetically unrelated White British participants without CVD. Levels of ambient particulate matter with a diameter of <2.5 μm (PM2.5) and <10 μm were estimated using land use regression models. An individual's genetic predisposition to CVDs was determined by polygenic risk scores for coronary artery disease, myocardial infarction, stroke, ischemic stroke, heart failure, and atrial fibrillation. We stratified mortality and CVD risk by PM2.5 exposure across high and low genetic risk groups. A total of 249 082 participants (aged 56.9±8.0 years, 46.8% men) were followed for a median of 10.8 years. The combined effect of PM2.5 exposure and the genetic predisposition of CVD demonstrated the highest risk of cardiovascular death in the high genetic risk group with the greatest PM2.5 exposure (adjusted hazard ratios ranging from 1.73 to 2.12 across the polygenic risk score of each CVD). The combination of higher exposure to ambient PM2.5 and high genetic risk was associated with higher incidence of all CVDs, although no significant interactions were observed between genetic risk and PM2.5 exposure on cardiovascular death or CVD events.
CONCLUSIONS: A combination of greater PM2.5 exposure and higher genetic predisposition to particular CVDs was modestly associated with elevated risks of cardiovascular death and CVDs. Not only alleviating PM2.5 exposure in the general population but also implementing individualized preventive approach for those at high genetic risk might be beneficial.
Patients will receive a placebo dose of all three study medications: Patients will receive the pre-operative dose of IV normal saline placebo within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of 20 mL of subcutaneous normal saline placebo after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive an IM dose of normal saline placebo.